Markers to define ischemia: Are they ready for prime time use in patients with acute coronary syndromes?
- Jesse Adams MD
- … show all 1 hide
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Optimal treatment of patients who present with chest pain is predicated on accurate identification of those patients with a cardiac etiology of their discomfort. Serial troponins and electrocardiograms are very sensitive for the detection of myocardial infarction but they are insensitive for the detection of ischemia. There are many analytes that are being actively evaluated for routine use to facilitate the identification of patients with myocardial ischemia. At present, only one assay is US Food and Drug Administration-approved for the exclusion of ischemia; many other analytes are under clinical evaluation and are briefly reviewed. At present, none of these analytes are yet appropriate for routine clinical use.
- Hamm CW, Braunwald E: A classification of unstable angina revisited. Circulation 2000, 102:118–122. An excellent review of the pertinent etiologic biology of ACS; necessary to understand the application of markers.
- Braunwald E, Antman EM, Beasley JW, et al.: ACC/AHA guidelines for the management of patients with unstable angina and non- ST segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). J Am Coll Cardiol 2000, 36:970–1062. The current consensus document for the accepted evaluation and treatment of patients who present with ACS. CrossRef
- Pope JH, Selker HP: Diagnosis of acute cardiac ischemia. Emerg Med Clin North Am 2003, 21:27–59. CrossRef
- Selker HP, Zalenski RJ, Antman EM, et al.: An evaluation of technologies for identifying acute cardiac ischemia in the emergency department: a report from a National Heart Attack Alert Program working group. Ann Emerg Med 1997, 29:13–87. CrossRef
- Apple FS, Quist HE, Doyle PJ, et al.: Plasma 99th percentile reference limits for cardiac troponin and creatine kinase MB mass for use with European Society of Cardiology/American College of Cardiology consensus recommendations. Clin Chem 2003, 49:1331–1336. The overview of the best contemporary cutpoints to use for troponin testing. CrossRef
- Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation 2002, 105:1135–1143. CrossRef
- Liuzzo G, Biasucci LM, Rebuzzi AG, et al.: Plasma protein acute-phase response in unstable angina is not induced by ischemic injury. Circulation 1996, 94:2373–2380.
- Sabatine MS, Morrow DA, de Lemos JA, et al.: Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 2002, 105:1760–1763. CrossRef
- Myocardial infarction redefined: a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. J Am Coll Cardiol 2000, 36:959–969. Myocardial infarction redefined for the current diagnostic age; this is the current paradigm for marker diagnostics.
- Antman EM, Tanasijevic MJ, Thompson B, et al.: Cardiacspecific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996, 335:1342–1349. CrossRef
- Jaffe AS: Testing the wrong hypothesis: the failure to recognize the limitations of troponin testing. J Am Coll Cardiol 2001, 38:999–1001. An excellent overview of the limitation of diagnostic assays. The issues raised here are critical for assessment of these relatively scantily evaluated markers of ischemia. CrossRef
- McDonough JL, Labugger R, Van Eyk JE: Prepare to meet your markers: making the most of troponin degradation. In Markers in Cardiology: Current and Future Clinical Applications. Edited by Adams JE, Apple FS, Jaffe AS, Wu AHB. Armonk, NJ: Futura; 2001:13–21.
- Feldman L, Rouleau C: Troponin I inhibits endothelial cell proliferation by interaction with the cell’s bFGF receptor. Microvasc Res 2002, 63:41–49. CrossRef
- Moses MA, Wiederschain D, Wu I, et al.: Troponin I is present in human cartilage and inhibits angiogenesis. Proc Natl Acad Sci U S A 1999, 96:2645–2650. CrossRef
- Schonbeck U, Varo N, Libby P, et al.: Soluble CD40L and cardiovascular risk in women. Circulation 2001, 104:2266–2268.
- Varo N, de Lemos JA, Libby P, et al.: Soluble CD40L risk prediction after acute coronary syndromes. Circulation 2003, 108:1049–1052. CrossRef
- Heeschen C, Dimmler S, Hamm CW, et al.: Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003, 348:1104–1111. CrossRef
- Danne O, Mockel M, Lueders C, et al.: Prognostic implications of elevated whole blood choline levels in acute coronary syndromes. Am J Cardiol 2003, 91:1060–1067. CrossRef
- Blankenberg S, Rupprecht HJ, Bickel C, et al.: Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. N Engl J Med 2003, 349:1605–1613. CrossRef
- Singa MK, Roy D, Gaze DC, et al.: Role of “ischemia modified albumin,” a new biochemical marker of myocardial ischemia, in the early diagnosis of acute coronary artery syndromes. Emerg Med J 2004, 21:29–34. This article is the best assessment yet of the only FDA-approved assay, IMA, for the exclusion of ischemia. CrossRef
- Brennan ML, Penn MS, Van Lente F, et al.: Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003, 349:1595–1604. CrossRef
- Baldus S, Heeschen C, Meinertz T, et al., for the CAPTURE investigators: Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003, 108:1440–1445. CrossRef
- James SK, Lindahl B, Siegbahn A, et al.: N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease. Circulation 2003, 108:275–281. CrossRef
- Morrow DA, Braunwald E: Future of biomarkers in acute coronary syndromes. Circulation 2003, 108:250–252. An excellent review of the potential of application of a multimarker strategy for the detection of ACS. CrossRef
- Lund J, Qin QP, Ilva T, et al.: Circulating pregnancy-associated plasma protein a predicts outcome in patients with acute coronary syndrome but no troponin I elevation. Circulation 2003, 108:1924–1926. CrossRef
- Kleinfeld AM, Kleinfeld KJ, Adams JE: Serum levels of unbound free fatty acids reveal high sensitivity for early detection of acute myocardial infarction in patient samples from the TIMI II trial. J Am Coll Cardiol 2002, 39:413A. CrossRef
- Adams JE, Kleinfeld A, Roe M, et al.: Measurement of levels of unbound free fatty acid allows the early identification of patients with acute coronary syndromes [abstract]. Circulation 2002,105:1–324. CrossRef
- Markers to define ischemia: Are they ready for prime time use in patients with acute coronary syndromes?
Current Cardiology Reports
Volume 6, Issue 4 , pp 253-258
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links
- Jesse Adams MD (1)
- Author Affiliations
- 1. Division of Cardiology, University of Louisville, 100 Mallard Creek, Suite 390, 40202, Louisville, KY, USA